

Medical Officer's review of New Drug Application No. 16-618 by James M. Moser, Jr., M.D., Division of Neuropharmacological Drugs, Mar. 25, 1970-----	Page 15338
Letter dated July 9, 1970, to Charles E. Edwards, M.D., Commissioner, Food and Drug Administration, from E. Claiborne Robins, A. H. Robins Co., Inc-----	15338
Memorandum dated Aug. 6, 1970, to Dorothy S. Dobbs, M.D., Director, Bureau of Drugs, from Martha M. Freeman, M.D., Division of Neuropharmacological Drugs, Food and Drug Administration-----	15341
Memorandum dated Oct. 8, 1970, to all medical officers, Bureau of Drugs, from Marvin Seife, M.D., Acting Director, Office of Scientific Evaluation Bureau of Drugs, Food and Drug Administration-----	15345
Minutes of 47th meeting of the Research Committee, Bureau of Drugs, Food and Drug Administration, Oct. 29, 1970-----	15346
Letter dated Aug. 31, 1971, to the Food and Drug Administration, from F. A. Clark, Jr., M.D-----	15347
Letter dated Mar. 7, 1975, to Alexander M. Schmidt, M.D., Commissioner, Food and Drug Administration, from Robert O. Knox, M.D., Medical Officer, Division of Oncology and Radiopharmaceuticals, Food and Drug Administration-----	15348
Letter dated Mar. 13, 1975, to Alexander M. Schmidt, M.D., Commissioner, Food and Drug Administration, from J. Richard Crout, M.D., Director, Bureau of Drugs, Food and Drug Administration-----	15356

HEARING DATES

Nov. 9, 1976: Morning session-----	14433
Nov. 10, 1976: Morning session-----	14469
Nov. 11, 1976: Morning session-----	14499
Nov. 18, 1976: Morning session-----	14529
Nov. 19, 1976: Morning session-----	14563